Log in

SKNY LIR Life Sciences Corp. CSE · Canada

LIR Life Sciences (SKNY) news

LIR Life Sciences Corp. is a public biotech or pharmaceutical company listed on CSE under the ticker SKNY, recorded under Canada. The directory classifies it as Preclinical drug-delivery developer. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest LIR Life Sciences news

We have not published a story on LIR Life Sciences yet. When there is news, it will appear here.

Questions about LIR Life Sciences

What is the ticker symbol of LIR Life Sciences?

LIR Life Sciences Corp. trades under the ticker SKNY on CSE.

Where is LIR Life Sciences listed?

LIR Life Sciences Corp. is listed on CSE.

Which country or territory is LIR Life Sciences listed under?

Our directory records LIR Life Sciences Corp. under Canada.

What does LIR Life Sciences do?

Our directory classifies LIR Life Sciences Corp. as: Preclinical drug-delivery developer. This is a directory classification, not a description of the pipeline.

What is the ISIN of LIR Life Sciences?

The ISIN recorded for LIR Life Sciences Corp. is CA50206C1005.

Does aibio.space cover LIR Life Sciences?

aibio.space lists LIR Life Sciences Corp. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to LIR Life Sciences?

Companies in our directory listed in the same country and business area as LIR Life Sciences: NORTH BUD FARMS INC, Devonian Health Group, Resverlogix, Hemostemix, BetterLife Pharma, Clearmind Medicine.

Investor discussion: LIR Life Sciences

Members talk about LIR Life Sciences (SKNY). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open CSE:SKNY on TradingView.

Listing details

LIR Life Sciences Corp. is a public biotech or pharmaceutical company listed on CSE under the ticker SKNY, recorded under Canada. The directory classifies it as Preclinical drug-delivery developer. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
LIR Life Sciences Corp.
Ticker
SKNY
Listing
CSE
Country or territory
Canada
Business scope
Preclinical drug-delivery developer
ISIN
CA50206C1005
Last quote in directory
2026-10-21
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.